Literature DB >> 17254516

The renin-angiotensin system and insulin resistance.

Zhenqi Liu1.   

Abstract

Insulin resistance upregulates the renin-angiotensin system (RAS), which contributes to the pathogenesis of hypertension, heart failure, and atherosclerosis. RAS inhibition decreases cardiovascular and renal morbidity and mortality and the incidence of new-onset type 2 diabetes. To the same degree, angiotensin II impairs insulin signaling, induces inflammation via the nuclear factor-kappaB pathway, and reduces nitric oxide availability and facilitates vasoconstriction, leading to insulin resistance and endothelial dysfunction. Thus, the RAS, insulin resistance, and inflammation perpetuate each other and coordinately contribute to endothelial dysfunction, vascular injury, and atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17254516     DOI: 10.1007/s11892-007-0007-5

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   5.430


  62 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

Review 2.  Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome.

Authors:  Abhiram Prasad; Arshed A Quyyumi
Journal:  Circulation       Date:  2004-09-14       Impact factor: 29.690

Review 3.  Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age.

Authors:  Robert M Carey
Journal:  Hypertension       Date:  2005-02-28       Impact factor: 10.190

Review 4.  Critical nodes in signalling pathways: insights into insulin action.

Authors:  Cullen M Taniguchi; Brice Emanuelli; C Ronald Kahn
Journal:  Nat Rev Mol Cell Biol       Date:  2006-02       Impact factor: 94.444

5.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

Review 6.  Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.

Authors:  Jeong-a Kim; Monica Montagnani; Kwang Kon Koh; Michael J Quon
Journal:  Circulation       Date:  2006-04-18       Impact factor: 29.690

7.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

8.  Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium.

Authors:  Etto C Eringa; Coen D A Stehouwer; Geerten P van Nieuw Amerongen; Lenneke Ouwehand; Nico Westerhof; Pieter Sipkema
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-04-01       Impact factor: 4.733

9.  Effect of AT1 receptor blockade on endothelial function in essential hypertension.

Authors:  Arnfried U Klingbeil; Stefan John; Markus P Schneider; Johannes Jacobi; Renate Handrock; Roland E Schmieder
Journal:  Am J Hypertens       Date:  2003-02       Impact factor: 2.689

10.  Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells.

Authors:  Francesco Andreozzi; Emanuela Laratta; Angela Sciacqua; Francesco Perticone; Giorgio Sesti
Journal:  Circ Res       Date:  2004-03-25       Impact factor: 17.367

View more
  19 in total

1.  Direct Activation of Angiotensin II Type 2 Receptors Enhances Muscle Microvascular Perfusion, Oxygenation, and Insulin Delivery in Male Rats.

Authors:  Fei Yan; Zhaoshun Yuan; Nasui Wang; Robert M Carey; Kevin W Aylor; Li Chen; Xinmin Zhou; Zhenqi Liu
Journal:  Endocrinology       Date:  2018-02-01       Impact factor: 4.736

2.  Losartan increases muscle insulin delivery and rescues insulin's metabolic action during lipid infusion via microvascular recruitment.

Authors:  Nasui Wang; Weidong Chai; Lina Zhao; Lijian Tao; Wenhong Cao; Zhenqi Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-01-08       Impact factor: 4.310

3.  Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.

Authors:  Weidong Chai; Wenhui Wang; Jia Liu; Eugene J Barrett; Robert M Carey; Wenhong Cao; Zhenqi Liu
Journal:  Hypertension       Date:  2009-12-07       Impact factor: 10.190

Review 4.  Hypertension management and microvascular insulin resistance in diabetes.

Authors:  Seung-Hyun Ko; Wenhong Cao; Zhenqi Liu
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

5.  Angiotensin-(1-7) recruits muscle microvasculature and enhances insulin's metabolic action via mas receptor.

Authors:  Zhuo Fu; Lina Zhao; Kevin W Aylor; Robert M Carey; Eugene J Barrett; Zhenqi Liu
Journal:  Hypertension       Date:  2014-04-07       Impact factor: 10.190

6.  Eplerenone inhibits aldosterone-induced renal expression of cyclooxygenase.

Authors:  Ma Bayorh; A Rollins-Hairston; J Adiyiah; D Lyn; D Eatman
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2012-05-03       Impact factor: 1.636

Review 7.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 8.  Emerging role of adipose tissue hypoxia in obesity and insulin resistance.

Authors:  J Ye
Journal:  Int J Obes (Lond)       Date:  2008-12-09       Impact factor: 5.095

9.  Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment.

Authors:  Paschalis Paschos; Konstantinos Tziomalos
Journal:  World J Hepatol       Date:  2012-12-27

Review 10.  Insulin and its role in chronic kidney disease.

Authors:  Robert H Mak
Journal:  Pediatr Nephrol       Date:  2007-10-11       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.